Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Qi Sun,1–3 Xiaoli Wang,1–3 Chunying Cui,1–3 Jing Li,1–3 Yifan Wang1–3 1Department of Pharmaceutics, School of Pharmaceutical Sciences, Capital Medical University, Beijing, China; 2Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, B...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sun Q, Wang X, Cui C, Li J, Wang Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Graphene oxide siRNA delivery co-delivery carrier cervical carcinoma Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fb0c085840b0432b8a206d0583525644
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb0c085840b0432b8a206d0583525644
record_format	dspace
spelling	oai:doaj.org-article:fb0c085840b0432b8a206d05835256442021-12-02T02:24:51ZDoxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo1178-2013https://doaj.org/article/fb0c085840b0432b8a206d05835256442018-06-01T00:00:00Zhttps://www.dovepress.com/doxorubicin-and-anti-vegf-sirna-co-delivery-via-nano-graphene-oxide-fo-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Qi Sun,1–3 Xiaoli Wang,1–3 Chunying Cui,1–3 Jing Li,1–3 Yifan Wang1–3 1Department of Pharmaceutics, School of Pharmaceutical Sciences, Capital Medical University, Beijing, China; 2Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Beijing, China; 3Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing, China Background: Graphene oxide (GO) has attracted intensive interest in biological and medical fields in recent years due to its unique physical, chemical, and biological properties. In our previous work, we proved that GO could deliver small interfering RNA (siRNA) into cells and downregulate the expression of the desired gene. Methods: This study investigated the potential of a modified GO nanocarrier for co-delivery of siRNA and doxorubicin (DOX) for enhanced cancer therapy. Fourier transform infrared spectroscopy, laser particle size analyzer, UV-visible spectroscopy, gel electrophoresis retardation, and in vitro release assay were studied. Results: The results of real-time polymerase chain reaction revealed that the expression of vascular endothelial growth factor (VEGF) mRNA was decreased 46.84%±3.72% (mean ± SD). Enzyme-linked immunosorbent assay indicated that the expression of VEGF protein was downregulated to 52.86%±1.10% (mean ± SD) in vitro. In vivo tumor growth assay GO-poly-L-lysine hydrobromide/folic acid (GPF)/DOX/siRNA exhibited gene silencing and tumor inhibition (66.95%±2.35%, mean ± SD) compared with naked siRNA (1.62%±1.47%, mean ± SD) and DOX (33.63%±5.85%, mean ± SD). GPF/DOX/siRNA exhibited no testable cytotoxicity. Conclusion: The results indicated that co-delivery of siRNA and DOX by GPF could be a promising application in tumor clinical therapy. Keywords: graphene oxide, siRNA delivery, co-delivery carrier, cervical carcinomaSun QWang XCui CLi JWang YDove Medical PressarticleGraphene oxidesiRNA deliveryco-delivery carriercervical carcinomaMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 3713-3728 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Graphene oxide siRNA delivery co-delivery carrier cervical carcinoma Medicine (General) R5-920
spellingShingle	Graphene oxide siRNA delivery co-delivery carrier cervical carcinoma Medicine (General) R5-920 Sun Q Wang X Cui C Li J Wang Y Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo
description	Qi Sun,1–3 Xiaoli Wang,1–3 Chunying Cui,1–3 Jing Li,1–3 Yifan Wang1–3 1Department of Pharmaceutics, School of Pharmaceutical Sciences, Capital Medical University, Beijing, China; 2Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Beijing, China; 3Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing, China Background: Graphene oxide (GO) has attracted intensive interest in biological and medical fields in recent years due to its unique physical, chemical, and biological properties. In our previous work, we proved that GO could deliver small interfering RNA (siRNA) into cells and downregulate the expression of the desired gene. Methods: This study investigated the potential of a modified GO nanocarrier for co-delivery of siRNA and doxorubicin (DOX) for enhanced cancer therapy. Fourier transform infrared spectroscopy, laser particle size analyzer, UV-visible spectroscopy, gel electrophoresis retardation, and in vitro release assay were studied. Results: The results of real-time polymerase chain reaction revealed that the expression of vascular endothelial growth factor (VEGF) mRNA was decreased 46.84%±3.72% (mean ± SD). Enzyme-linked immunosorbent assay indicated that the expression of VEGF protein was downregulated to 52.86%±1.10% (mean ± SD) in vitro. In vivo tumor growth assay GO-poly-L-lysine hydrobromide/folic acid (GPF)/DOX/siRNA exhibited gene silencing and tumor inhibition (66.95%±2.35%, mean ± SD) compared with naked siRNA (1.62%±1.47%, mean ± SD) and DOX (33.63%±5.85%, mean ± SD). GPF/DOX/siRNA exhibited no testable cytotoxicity. Conclusion: The results indicated that co-delivery of siRNA and DOX by GPF could be a promising application in tumor clinical therapy. Keywords: graphene oxide, siRNA delivery, co-delivery carrier, cervical carcinoma
format	article
author	Sun Q Wang X Cui C Li J Wang Y
author_facet	Sun Q Wang X Cui C Li J Wang Y
author_sort	Sun Q
title	Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo
title_short	Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo
title_full	Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo
title_fullStr	Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo
title_full_unstemmed	Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo
title_sort	doxorubicin and anti-vegf sirna co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/fb0c085840b0432b8a206d0583525644
work_keys_str_mv	AT sunq doxorubicinandantivegfsirnacodeliveryviananographeneoxideforenhancedcancertherapyinvitroandinvivo AT wangx doxorubicinandantivegfsirnacodeliveryviananographeneoxideforenhancedcancertherapyinvitroandinvivo AT cuic doxorubicinandantivegfsirnacodeliveryviananographeneoxideforenhancedcancertherapyinvitroandinvivo AT lij doxorubicinandantivegfsirnacodeliveryviananographeneoxideforenhancedcancertherapyinvitroandinvivo AT wangy doxorubicinandantivegfsirnacodeliveryviananographeneoxideforenhancedcancertherapyinvitroandinvivo
_version_	1718402507442487296

Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Ejemplares similares